FREMONT, CA, Oct. 26, 2023 (GLOBE NEWSWIRE) — via NewMediaWire- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a legal binding term sheet regarding a multi-year, global licensing agreement with AiBtl…Read More
ABVC BioPharma Inc ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of 667 Million
